# A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

> **NCT07029828** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 140 (estimated)

## Conditions studied

- Severe Alopecia Areata

## Interventions

- **DRUG:** Ritlecitinib higher dose
- **DRUG:** Ritlecitinib lower dose

## Key facts

- **NCT ID:** NCT07029828
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2030-06-26
- **Final completion:** 2030-06-26
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029828, "A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07029828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*